Abstracts tagged "Animal Model"

Abstract Number: 0797 • ACR Convergence 2023
Innate Lymphoid Cells Enhance Development of CD4+ T-cell Driven Autoimmune Arthritis
Agnieszka Lastowska¹, Charlotte E. van der Plas¹, Anders Nguyen¹, Symeon Kourmoulakis¹, Miriam Bollmann¹ and Mattias N.D Svensson², ¹Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Innate Lymphoid cells (ILCs) are innate counterparts to T-cells that, based on their functional phenotype, can be divided into three subpopulations called Group 1…
Abstract Number: 0953 • ACR Convergence 2023
Flavin-containing Monooxygenase (FMO3) Links the Gut and Fibrosis in Systemic Sclerosis
Priyanka Verma¹, Bharath Yalavarthi¹, Karen Ho², Lutfiyya Muhammad³, Seokjo Kim⁴, Johann Gudjonsson¹, Rebecca C Schugar⁵, Mark Brown⁶, Xinmin Li⁶, Stanley L Hazen⁷, Swati Bhattacharyya¹ and John Varga¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴4SCM Lifescience Co. Ltd, South Korea, Japan, ⁵Stanford University, Stanford, CA, ⁶Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, ⁷Division of Endocrinology, Department of Medicine, Stanford University, Stanford, CA
Background/Purpose: Trimethylamine (TMA) generated by the gut microbiome is converted into trimethylamine N-oxide (TMAO) via the host enzyme FMO3. The TMA-FMO3-TMAO metaorganismal axis has been…
Abstract Number: 1864 • ACR Convergence 2023
Quantifying Inflammation: A Novel In-Vivo Total Body PET Imaging Tool to Determine the Kinetics of the Degree of Changes in Inflammation in Different Time Points
Siba Raychaudhuri¹, Sanchita Raychaudhuri², Naveen Chandrasekar³, Christine Abria³, Sneha Banerjee³, Smriti K Raychaudhuri³ and Abhijit Chaudhari², ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²UC Davis School of Medicine, Sacramento, CA, ³VA Sacramento Medical Center, Mather, CA
Background/Purpose: Collagen‐induced arthritis (CIA) mouse model is one of the best recognized animal model for autoimmune diseases. In this model clinical methods of evaluating inflammation…
Abstract Number: 0804 • ACR Convergence 2023
Mutated NOD2 Controls IL-2 Production in Blau Syndrome Patients and Mice
Leah M. Huey¹, Emily Vance¹, Holly L. Rosenzweig², Bryce Binstadt³ and Ruth J. Napier², ¹Oregon Health & Science University, Portland, OR, ²Oregon Health & Science University, VA Portland Health Care System, Portland, OR, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Microbial sensing molecule nucleotide-binding oligomerization-domain containing protein 2 (NOD2) is expressed by CD4+ T cells and plays a novel T cell-intrinsic role within CD4+…
Abstract Number: 1322 • ACR Convergence 2023
Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Christoph Burkart, Clara Polizzi, Lisa Eide, Max Pastenes, David Siefker and Leslie Nangle, aTyr Pharma, San Diego, CA
Background/Purpose: Efzofitimod, a novel immunomodulator, has shown clinical proof-of-concept in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis and is currently enrolling a…
Abstract Number: 2437 • ACR Convergence 2023
Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy
Benjamin Cai¹, Rabina Giri², Helen Benham³, Linda Rehaume¹, Geoffery Strutton³, Anne-Sophie Bergot¹ and Ranjeny Thomas⁴, ¹Frazer Institute, The University of Queensland, Woolloongabba, Australia, ²Mater Research Institute-UQ, Woolloongabba, Australia, ³Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Frazer Institute, The University of Queensland, Brisbane, Australia
Background/Purpose: In spondylarthropathy (SpA), such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS), arthritis is often associated with gut inflammation. After systemic β-1,3-glucan (curdlan) injection,…
Abstract Number: 0860 • ACR Convergence 2023
Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation
Chandramohan Natarajan¹, Julia Lucchino¹, David Chenoff² and Yaakov Levine¹, ¹SetPoint Medical, Valencia, CA, ²SetPoint Medical, Sausalito, CA
Background/Purpose: Electrical stimulation of the vagus nerve activates the inflammatory reflex to inhibit cytokines and decrease clinical signs and symptoms of chronic inflammatory disease such…
Abstract Number: 1342 • ACR Convergence 2023
The Delivery of the Super-repressor IκBα by Exosomes Has the Potential to Alleviate Inflammation Associated with Rheumatoid Arthritis
Ki-Jeong Park¹, Ji-Hyoun Kang¹, Hae-In Lee², Yu Jeong Lee¹, Moon-Ju Kim¹, So-Hee Ahn³, Jae-Kwang Yoo³, Chulhee Choi³ and Tae-jong Kim⁴, ¹Chonnam National University Hospital, Gwangju, South Korea, ²Chonnam National University, Gwangju, South Korea, ³ILIAS Biologics, Daejeon, South Korea, ⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is a persistent inflammatory disease primarily affecting the diarthrodial joints. Nuclear factor-κB (NF-κB) is a family of inducible transcription factors responsible…
Abstract Number: 2444 • ACR Convergence 2023
Development of Engineered Smith-Specific Regulatory T Cells to Treat Lupus Nephritis
Eric Morand¹, Rachel Cheong², Peter Eggenhuizen², Janet Chang², Ashraf Broury², Boaz Ng², Khai Loh², Elean Tay², Chanjuan Shen³, Julie Monk², Yong Zhong⁴, Steven Lim², Jia Xi Chung², Rangi Kandane-Rathnayake⁵, Rachel Koelmeyer², Alberta Hoi⁶, Sarah Snelgrove², Yi Tian Ting² and Joshua Ooi², ¹Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ²Monash University, Clayton, Australia, ³Central South University, Changsha, China, ⁴Xiangya Hospital, Central South University, Changsha, China, ⁵Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, ⁶Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia
Background/Purpose: Regulatory T cells (Tregs) play an important role in maintaining immune system homeostasis. Antigen-specific Tregs potently and specifically suppress autoreactivity, suggesting their potential to…
Abstract Number: 0861 • ACR Convergence 2023
The Analgesic Effect of RC-0165, a TRPV1 Antagonist, for Osteoarthritis Pain
Donghui kim, Juil park, Minjung kim and Yongho kim, RudaCure, Seoul, South Korea
Background/Purpose: Osteoarthritis (OA), the most common form of arthritis, arises from the deterioration of cartilage within joint bones, resulting in pain and functional disability with…
Abstract Number: 1370 • ACR Convergence 2023
Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration
Eui-Jong Kwon¹, Jin-Sil Park², Ha Yeon Jeong³, Hye Yeon Kang⁴, JeongWon Choi³, Mi-La Cho³ and Sung-Hwan Park⁵, ¹Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Seocho-gu, South Korea, ²The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ³Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Sjogren’s syndrome (SS) is a systemic autoimmune disease characterized by infiltration of lymphocytes into the exocrine gland resulting in progressive lacrimal and salivary estruction…
Abstract Number: 2445 • ACR Convergence 2023
Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis
Dayvia Russell¹, Sandra Sanchez², Evelyn Bruner² and Jim Oates², ¹Ralph H. Johnson VA Medical Center, Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis (LN) constitutes one of the most severe manifestations of systemic lupus erythematosus (SLE). Evidence points to endothelial nitric oxide synthase (eNOS) uncoupling,…
Abstract Number: 0867 • ACR Convergence 2023
Pentosan Polysulfate Sodium, a Glycosaminoglycan Mimetic Demonstrates Durable Effects on Pain, Function and Joint Structure in Canine Naturally Occurring Osteoarthritis
Ravi Krishnan¹, Catherine Stapledon², Christian Reiter², Stewart Ryan³, Sebastien Bauquier³ and Thierry Beths³, ¹Paradigm Biopharmaceuticals, Adelaide, Australia, ²Paradigm Biopharmaceuticals, Melbourne, Australia, ³U-Vet Werribee Animal Hospital, University of Melbourne, Melbourne, Australia
Background/Purpose: Pentosan Polysulfate sodium (PPS) is a semi-synthetic polysaccharide and a glycosaminoglycan mimetic. The multiple actions of PPS involve anti-inflammatory effects via inhibition of NF-κB;…
Abstract Number: 1594 • ACR Convergence 2023
Oral Delivery of Δ9-Tetrahydrocannabinol Provides Symptom and Disease Modification in a Mouse Model of Knee Osteoarthritis
Jason rockel¹, Anca Maglaviceanu², Helena Fetter Filippini³, Ewa Wasilewski⁴, Melissa M. Lewis-Bakker⁴, Sarah Gabrial¹, Evgeny Rossomacha¹, Johana Garcia¹, Nizar Mahomed⁵, Timothy Leroux⁵, Hance Clarke⁶, Robert P. Bonin³, Lakshmi P. Kotra⁷ and Mohit Kapoor¹, ¹Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ³Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada, ⁴Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, Krembil Research Institute, and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶Krembil Research Institute, and Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, ON, Canada, ⁷Krembil Research Institute, University Health Network; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Background/Purpose: Osteoarthritis (OA) results in joint pain, cartilage degeneration, and synovitis. Recent studies suggest that some OA patients are self-medicating with cannabis. Δ9-tetrahydrocannabinol (THC) is…
Abstract Number: 0870 • ACR Convergence 2023
Targeting Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Therapy for Osteoarthritis
Uxía nogueira Recalde¹, Patricia Díaz rodríguez², Francisco J. Blanco³, Eduardo Dominguez Medina⁴ and Beatriz Carames⁵, ¹Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomedica de A Coruña (iNIBIC), A Coruña, Spain, ²Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Pharmacy School, Santiago de Compostela, Spain, ³Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ⁴Center for Research in Molecular Medicine and Chronic Diseases, Santiago de Compostela, Spain, ⁵Unidad de Biología del Cartílago, Grupo de Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain
Background/Purpose: Disease-modifying therapeutic agents to prevent progression of Osteoarthritis (OA) are an urgent clinical need. Targeting senescence and autophagy in chondrocytes with small molecules is…

« Previous Page
1
…
3
4
5
6
7
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.